TGFB1 and Hepatic fibrosis: Given that losartan has a protective effect on TGF-β1-induced skeletal muscle injury as well as liver fibrosis [25,44], it could be potentially used as a clinical therapeutic for skeletal muscle diseases induced by aging and other chronic diseases such as chronic liver fibrosis as well as chronic muscle atrophy, sarcopenia, and muscular fibrosis.